Abstract:Objective: To determine the efficacy of first-generation single-agent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy in advanced non-small-cell lung cancer patients with known EGFR mutation status, we undertook this pooled analysis. Method: We searched for randomized controlled trials (RCTs) in Medline, Embase, the Cochrane Controlled Trials Register, the Science Citation Index, and the American Society of Clinical Oncology annual meetings. Results: Out of 2,129 retrieved articles, 19 RCTs enrolling 2,016 patients with wild-type EGFR tumors and 1,034 patients with mutant EGFR tumors were identified. For these EGFR mutant patients, single-agent EGFR-TKI therapy improved progression-free survival (PFS) over chemotherapy: the summary hazard ratios (HRs) were 0.41 (p < 0.001) for the first-line setting and 0.46 (p = 0.02) for the second-/third-line setting. For those EGFR wild-type patients, single-agent EGFR-TKI therapy did not do as well as chemotherapy in the first-line setting (HR = 1.65, p = 0.03) and in the second-/third-line setting (HR = 1.27, p = 0.006). No statistically significant difference was observed in terms of overall survival (OS). Using platinum-based doublet chemotherapy as a common comparator, indirect comparison showed the superior efficacy of single-agent EGFR-TKI therapy over EGFR-TKIs added to chemotherapy in PFS [HR = 1.35 (1.03, 1.77), p = 0.03]. Additionally, a marginal trend towards the same direction was found in the OS analysis [HR = 1.16 (0.99, 1.35), p = 0.06]. Interestingly, for those EGFR wild-type tumors, single-agent EGFR-TKI therapy was inferior to EGFR-TKIs added to chemotherapy in PFS [HR = 0.38 (0.33, 0.44), p < 0.001] and OS [HR = 0.83 (0.71, 0.97), p = 0.02]. Conclusions: For these EGFR mutant patients, single-agent EGFR-TKI therapy prolonged PFS over chemotherapy. However, single-agent EGFR-TKI therapy was inferior to chemotherapy in PFS for those EGFR wild-type patients. Single-agent EGFR-TKI therapy could improve PFS over the combination of EGFR-TKIs and chemotherapy in these EGFR mutant patients. However, EGFR-TKIs combined with chemotherapy could provide additive PFS and OS benefit over single-agent EGFR-TKI therapy in those EGFR wild-type patients. (C) 2016 S. Karger AG, Basel

Efficacy of Epidermal Growth Factor Receptor (Egfr)-Tyrosine Kinase Inhibitors (tkis) in Targeted Therapy of Lung Squamous Cell Carcinoma Patients with EGFR Mutation: a Pooled Analysis.

167P: Efficacy of EGFR-TKIs for Lung Squamous Carcinomas Harboring EGFR Mutation: A Multicenter Study and Pooled Analysis of Published Reports

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes after Treatment with EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

Efficacy of epidermal growth factor receptor–tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports

How Sensitive Are Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor for Lung Adenosquamous Cell Carcinoma Harboring EGFR Mutation? A Bicenter Research and Pooled Analysis of Published Reports.

Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor for lung adenosquamous cell carcinoma harboring EGFR mutation: a retrospective study and pooled analysis

Epidermal Growth Factor Receptor‐tyrosine Kinase Inhibitor Therapy is Effective As First‐line Treatment of Advanced Non‐small‐cell Lung Cancer with Mutated EGFR: A Meta‐analysis from Six Phase III Randomized Controlled Trials

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Squamous Cell Lung Cancer.

Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors for Chinese Patients with Squamous Cell Carcinoma of Lung Harboring EGFR Mutation.

Progress on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor for Treatment of Advanced Non-Small Cell Lung Cancer

Prediction of Epidermal Growth Factor Receptor Mutations in the Plasma/pleural Effusion to Efficacy of Gefitinib Treatment in Advanced Non-Small Cell Lung Cancer.

Gefitinib or Erlotinib Vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

PUB047 Efficacy of EGFR-TKI for Lung Adenosquamous Cell Carcinoma Harboring EGFR Mutation

The Efficacy of Single-Agent Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Biologically Selected Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis of 19 Randomized Controlled Trials

Relationship Between Mutations of Epidermal Growth Factor Receptor in the Plasma and Pleural Effusion and Responses to Gefitinib in Advanced Pretreated Non-Small Cell Lung Cancer

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China

Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer

Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study

Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Recurrent Adenosquamous Carcinoma of the Lung after Resection

Analysis of Effectiveness of Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations Containing Rare Mutations

Efficacy and Predictors of Egfr Tyrosine Kinase Inhibitors in Chinese Advanced Lung Adenocarcinoma: Analyses of 253 Cases from A Single Institute